Veradigm Inc. (NASDAQ:MDRX – Get Free Report) has been given a consensus recommendation of “Hold” by the six brokerages that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $12.00.
MDRX has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $10.00 target price (down from $15.00) on shares of Veradigm in a report on Tuesday, March 19th. StockNews.com assumed coverage on Veradigm in a research report on Wednesday, June 26th. They issued a “hold” rating on the stock. Finally, TD Cowen cut their target price on Veradigm from $26.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday, May 28th.
Read Our Latest Analysis on Veradigm
Institutional Inflows and Outflows
Veradigm Stock Up 5.6 %
Shares of NASDAQ:MDRX opened at $9.50 on Wednesday. Veradigm has a fifty-two week low of $5.01 and a fifty-two week high of $14.09. The firm has a 50-day simple moving average of $8.57 and a 200 day simple moving average of $8.63.
About Veradigm
Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
Featured Stories
- Five stocks we like better than Veradigm
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- How to invest in blue chip stocks
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Veradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradigm and related companies with MarketBeat.com's FREE daily email newsletter.